TruSight Oncology 500 offers wide variety of benefits in analyzing multiple tumor variant types in 523 genes in a single assay. It is a next-generation sequencing (NGS) assay that enables comprehensive genomic profiling of tumor samples. The assay is highly effective in identifying all types of relevant DNA and RNA variants in different types of solid tumors including lung, melanoma, ovarian, breast, gastric, bladder, sarcoma etc.
Also, the assay is highly accurate in measuring immuno-oncology biomarkers such as microsatellite instability (MSI) and tumor mutational burden (TMB).
Our TST170 Panel is also validated on ctDNA. It also provides an indepth view into cancer genetics, effective in assessing fusions, splice variants, insertions/deletions and single-nucleotide variants (SNVs), and amplifications.
Solutions for cells, blood, tissues, FFPE with varying quality and quantity inputs
TruSight Oncology 500
TruSight Tumor 170
BioFX’s transcriptome analysis platform was built using state-of-the-art analysis tools for gene expression, differential expression, pathway enrichment, splicing and fusion analysis and more.
Drug gene interaction plot shows potential known/reported drug-gene interactions or Druggable categories for the 20 most frequently mutated genes.
MedGenome’s customer portal allows for easy sample submission and sample tracking during lab processing. Data QC, raw data and interactive analysis reports are delivered securely through customer portal.
MedGenome Inc. Services with Illumina’s TruSight Oncology 500 (TSO 500)
Illumina’s TSO 500 is a comprehensive assay that enables comprehensive genomic profiling of tumor samples. It is a single workflow identifying DNA and RNA variants from the same sample. It can detect InDels, SNVs, CNV, fusions and splice variants. It also measures biomarkers like Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI) using limited sample input. MedGenome uses propriety analysis pipeline along with Illumina’s Basespace platform to analyze data providing high sensitivity and specificity to provide a comprehensive cancer genomic profile.